Multiple myeloma (MM) is an incurable hematological malignancy characterized by the
clonal proliferation of neoplastic plasma cells. The use of proteasome inhibitors in the …

Bortezomib‐induced peripheral neuropathy (BIPN) is a common toxicity associated with the
treatment of multiple myeloma (MM), typically requiring dose reduction, delay, or cessation …

This overview summarizes evidence for the efficacy and safety of bortezomib, thalidomide,
and lenalidomide in patients with multiple myeloma. We searched the Medline, Scopus, and …

High-dose chemotherapies to treat multiple myeloma (MM) can be life-threatening due to
toxicities to normal cells and there is a need to target only tumor cells and/or lower standard …

Neurotoxic treatments (including proteasome inhibitors, immunomodulatory drugs and vinca-
alkaloids) are often used in the treatment of hematologic malignancy. Peripheral neuropathy …

In the past decades, considerable progress has been made in our understanding and
treatment of multiple myeloma. Several challenges remain including our abilities to …

Like other neurodegenerative diseases, Alzheimer Disease (AD) has a prominent
inflammatory component mediated by brain microglia. Reducing microglial inflammation …

Objective Transcatheter arterial chemoembolization (TACE) and thalidomide have been
used for treating primary hepatocellular carcinoma (HCC). This study aims to evaluate the …

Once-weekly bortezomib had similar effectiveness and lower t... : Medicine Once-weekly
bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with …

Lenalidomide is an immunomodulatory drug (IMiD), which is well established and approved
in the treatment of multiple myeloma (MM) and 5q-myelodysplastic syndrome (MDS). The …